Tuesday, June 11, 2019 4:23:15 AM
May-2019 vs. May-2018 (NORMALIZED Retail ONLY Data)
Amazing Year-On-Year Increase Across the Board; 76% increase in TRx & 85% increase in NRx & 69% increase in Refills
It is worth mentioning that V is driving the whole sector into positive green territory (Year-On-Year ~+15% TRx & ~+18% NRx & ~+12% Refills) and at the same time increasing its own Market Share
V
TRx: 261,008 {vs 148,261; +76.05%} – Sector +14.69% -- ATH (31,320,937 vs 17,791,365)
NRx: 124,153 {vs 67,104; +85.02%} – Sector +18.24% -- ATH (14,898,397 vs 8,052,488)
Ref: 136,855 {vs 81,157; +68.63%} – Sector +11.71% -- ATH (16,422,540 vs 9,738,877)
Gen L
TRx: 264,170 {vs 277,670; -4.86%} (31,700,430 vs 33,320,398)
NRx: 123,658 {vs 127,877; -3.30%} (14,838,959 vs 15,345,290)
L
TRx: 5,564 {vs 36,826; -84.89%} (667,687 vs 4,419,060)
NRx: 2,184 {vs 16,449; -86.72%} (262,105 vs 1,973,830)
V May-2019 NORMALIZED Retail ONLY TRx Market Share: 49.18% vs 32.04% in May-2018 --- ATH
V May-2019 NORMALIZED Retail ONLY NRx Market Share: 49.66% vs 31.74% in May-2018 --- ATH
V May-2019 NORMALIZED Retail ONLY Ref Market Share: 48.75% vs 32.29% in May-2018 --- ATH
1st 5 Month-2019 vs. 1st 5 Month-2018 (NORMALIZED Retail ONLY Data)
Again Amazing Year-On-Year Increase Across the Board & driving the whole sector up with it
V
TRx: 1,128,667 {vs 681,148; +65.70%} – Sector +12.93% --- ATH
NRx: 561,012 {vs 307,798; +82.27%} – Sector +22.45% --- ATH
Ref: 567,655 {vs 373,350; +52.04%} – Sector +5.21% --- ATH
Gen L
TRx: 1,331,774 {vs 1,339,664; -0.59 %}
NRx: 635,364 {vs 595,230; +6.74%}
L
TRx: 28,933 {vs 183,590; -84.24%}
NRx: 11,650 {vs 83,509; -86.05%}
V First 5M-2019 NORMALIZED Retail TRx Market Share: 45.34% vs 30.90% in First 5M-2018 -- ATH
V First 5M-2019 NORMALIZED Retail NRx Market Share: 46.44% vs 31.20% in First 5M-2018 --ATH
V First 5M-2019 NORMALIZED Retail Ref Market Share: 44.30% vs 30.66% in First 5M-2018 -- ATH
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM